By Associate Professor Meg Jardine

Preprints

Neuen B; Jun M; Wick J; Kotwal S; Badve S; Jardine M; Gallagher M; Chalmers J; Nallaiah K; Perkovic V; Peiris D; Rodgers A; Woodward M; Ronksley P, 2023, Estimating the population-level kidney benefits of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease in Australian primary care, http://dx.doi.org/10.1101/2023.06.26.23291881

Jun M; Wick J; Neuen B; Kotwal S; Badve S; Woodward M; Chalmers J; Peiris D; Rodgers A; Nallaiah K; Jardine M; Perkovic V; Gallagher M; Ronksley P, 2023, The prevalence of chronic kidney disease in Australian primary care: analysis of a national general practice dataset, http://dx.doi.org/10.1101/2023.06.18.23290762

McGree JM; Hockham C; Kotwal S; Wilcox A; Bassi A; Pollock C; Burrell LM; Snelling T; Jha V; Jardine M; Jones M; for the CLARITY Trial Steering Committee , 2021, Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY): Statistical analysis plan for a randomised controlled Bayesian adaptive sample size trial, http://dx.doi.org/10.1101/2021.08.17.21262196

Fu E; Trevisan M; Lanka V; Clase CM; Xu Y; van Diepen M; Dekker FW; Jardine MJ; Carrero J-J, Comparative Effectiveness of SGLT2i Versus DPP4i on Cardiovascular, Kidney and Hyperkalemia Outcomes in Individuals from Routine Clinical Practice: Observational Cohort Study, http://dx.doi.org/10.2139/ssrn.3947641

Fu E; Clase CM; Janse RJ; Lindholm B; Dekker FW; Jardine MJ; Carrero J-J, Comparative Effectiveness of SGLT2i Versus GLP1-RA on Cardiovascular Outcomes in Routine Clinical Practice, http://dx.doi.org/10.2139/ssrn.3947642

Back to profile page